Today's Top 5
5. Experts Explain the Latest Research in Kidney Cancer
#KidneyCancer patients from all over the world are welcome to join us for this brief "town hall" style virtual meeting to review the news from @ASCO #GU12 in patient-friendly language. Learn how the recent developments impact your treatment.
— KidneyCAN: The Kidney Cancer Coalition (@kidneycan) February 22, 2021
Register: https://t.co/mUGNe8YvG4 pic.twitter.com/fW6BYG7rQn
4. AstraZeneca Withdraws Durvalumab Indication for Bladder Cancer
AstraZeneca Withdraws Durvalumab Indication for Previously Treated Locally Advanced or Metastatic Bladder Cancer https://t.co/mxOUfXJ6WN via @CancerNetwrk
— Richard Schilsky (@rschilsky) February 23, 2021
3. Evolving Landscape of Biomarker Testing for NSCLC
The evolving landscape of #biomarker testing for #NSCLC in #Europe! Proud to be part of this great team of #Pathologist @OncoAlert @ChristianRolfo https://t.co/Wksb88JUMu pic.twitter.com/FTxsXbY2YN
— Umberto Malapelle (@UmbertoMalapel1) February 23, 2021
2. Cancer Research Dissemination in the Pandemic and Beyond
“Advances in #cancerresearch dissemination through the #pandemic and beyond” @Annals_Oncology https://t.co/53Xn1cTUjP @IshwariaMD @VivekSubbiah discuss the role of @Twitter, #podcasts, #PrePrints, and #VirtualEvents @COVID19nCCC @OncoAlert pic.twitter.com/XdgES9h8Gd
— Aakash Desai (@ADesaiMD) February 24, 2021
1. Review: Genetic Alterations in Pancreatic Cancer
If you are interested in the molecular alterations in pancreatic cancer, don't miss our new review. We discuss the main genetic alterations and molecular subtypes in PDA that should be taken in account in the design of new clinical trials. @PancreaticCell https://t.co/IGUJuagRko pic.twitter.com/p1qVXhM3gL
— Victor J Sanchez (@vjsanchez) February 22, 2021